CD274 and neoplasm: KEYNOTE 028 and KEYNOTE 199 phase II trial suggest that pembrolizumab can result in durable responses in castration-resistant prostate cancer as long as the tumors express PD-L1 in ≥1% of tumor or stromal cells.